MAZE
Maze Therapeutics, Inc.Healthcare · $1.5B market cap
Verdict
We can't put a fair value on MAZE right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow MAZE
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 1, 2026: no open-market purchases, 20 sales worth $2.7M and 5 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Bernstein Harold
President, R&D & CMO · 2026-09-04
Sold
$255K
Bernstein Harold
President, R&D & CMO · 2026-09-03
Sold
$2K
Bernstein Harold
President, R&D & CMO · 2026-09-03
Sold
$133K
Coloma Jason V
Chief Executive Officer · 2026-09-03
Sold
$3K
Coloma Jason V
Chief Executive Officer · 2026-09-03
Sold
$293K
Show all 20 salesShow fewer
Dandekar Atul
CSBO · 2026-09-03
Sold
$929
Dandekar Atul
CSBO · 2026-09-03
Sold
$83K
Courtney Phillips
GC and Corp. Secretary · 2026-09-03
Sold
$567
Courtney Phillips
GC and Corp. Secretary · 2026-09-03
Sold
$52K
Bernstein Harold
President, R&D & CMO · 2026-09-02
Sold
$17K
Bernstein Harold
President, R&D & CMO · 2026-09-02
Sold
$118K
Coloma Jason V
Chief Executive Officer · 2026-09-02
Sold
$37K
Coloma Jason V
Chief Executive Officer · 2026-09-02
Sold
$260K
Dandekar Atul
CSBO · 2026-09-02
Sold
$11K
Dandekar Atul
CSBO · 2026-09-02
Sold
$74K
Courtney Phillips
GC and Corp. Secretary · 2026-09-02
Sold
$7K
Courtney Phillips
GC and Corp. Secretary · 2026-09-02
Sold
$46K
Bernstein Harold
President, R&D & CMO · 2026-09-01
Sold
$426K
Coloma Jason V
Chief Executive Officer · 2026-09-01
Sold
$839K
Coloma Jason V
Chief Executive Officer · 2026-09-01
Sold
$68K
Other filings
Bernstein Harold
President, R&D & CMO · 2026-09-01
Option exercise
20,000 shares
Bernstein Harold
President, R&D & CMO · 2026-09-01
Option exercise
$168K
Coloma Jason V
Chief Executive Officer · 2026-09-01
Option exercise
50,000 shares
Dandekar Atul
CSBO · 2026-09-01
Option exercise
12,500 shares
Courtney Phillips
GC and Corp. Secretary · 2026-09-01
Option exercise
11,000 shares
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works